Clinical Trial

A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer

Name: A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer — clinical trial record (NCT07349069)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The study is being conducted to evaluate the efficacy and safety of HRS-8080 in patients with intermediate or high risk early breast cancer.

Protocol Amendment History 1 change

notable Enrollment increased: 4800 -> 5500 participants 2026-05-23

Trial Details

NCT Number	NCT07349069
Lead Sponsor	Shandong Suncadia Medicine Co., Ltd.
Conditions	Breast Cancer
Enrollment	5,500 participants
Start Date	2026-03-04
Primary Completion	2030-12 (estimated)
Study Completion	2034-01 (estimated)
Updated on ClinicalTrials.gov	2026-05-22